|
|
Article: Takeda R&D meeting focuses on insomnia treatment Rozeram.(research and development)
- Article from:
- Pharma Marketletter
- Article date:
- August 1, 2005
CopyrightCOPYRIGHT 2005 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Japanese drug major Takeda presented its planned marketing strategies for Rozerem (ramelteon, TAK-375), an MT1/MT2 receptor agonist treatment for insomnia, at a recent R&D meeting with analysts. A New Drug Application was filed with US Food and Drug Administration in September 2004. This was approved on July 22 and Takeda expects a launch in that market around fall 2005. Rozerem is in Phase III clinical trials in Europe and Japan. Additionally, it is in Phase II testing in the USA for the treatment of circadian rhythm sleep disorders.
Takeda estimates that there are approximately 76 million potential insomnia patients (over 18 years old) in the USA alone. Of ...